<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161687">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00993655</url>
  </required_header>
  <id_info>
    <org_study_id>OV21</org_study_id>
    <secondary_id>CAN-NCIC-OV21</secondary_id>
    <secondary_id>UCL08/0379</secondary_id>
    <secondary_id>GEICO-0902</secondary_id>
    <secondary_id>SWOG OV.21</secondary_id>
    <secondary_id>CDR0000655241</secondary_id>
    <nct_id>NCT00993655</nct_id>
  </id_info>
  <brief_title>Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer</brief_title>
  <official_title>A Phase II Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grupo Español de Investigación en Cáncer de Ovario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work
      in different ways to stop the growth of tumor cells, either by killing the cells or by
      stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving
      them in different ways may kill more tumor cells. It is not yet known which combination
      chemotherapy regimen is more effective in treating patients with ovarian epithelial cancer,
      primary peritoneal cancer, and fallopian tube cancer.

      PURPOSE: This randomized phase II trial is comparing the side effects of three combination
      chemotherapy regimens and to see how well they work in treating patients with stage IIB,
      stage IIC, stage III, or stage IV ovarian epithelial cancer, primary peritoneal cancer, or
      fallopian tube cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine if intraperitoneal platinum-based chemotherapy leads to 9 month
           progression free survival rate as compared with intravenous chemotherapy in patients
           with stage IIB-III or stage IV (on the basis of pleural effusion only with positive
           cytology) ovarian epithelial, serous type peritoneal, or fallopian tube cancer who have
           received optimal debulking surgery following neoadjuvant intravenous chemotherapy.

        -  To identify which of the two IP regimens will continue into the expanded phase II
           portion of the trial.

        -  To compare the efficacy of the selected IP plus IV chemotherapy regimen versus IV
           carboplatin plus paclitaxel in these patients.

      Secondary

        -  To compare IP plus IV chemotherapy versus IV carboplatin plus paclitaxel with respect
           to progression free survival, overall survival, toxic effects, quality of life, and
           economic evaluation.

        -  To determine components of nursing interventions associated with administering
           intraperitoneal therapy and to correlate these interventions with treatment efficacy,
           toxic effects, and quality of life.

      OUTLINE: This is a multicenter study. Patients are stratified according to cooperative
      group, residual disease (observable [e.g., macroscopic] disease that is evident at end of
      delayed primary debulking surgery vs no evidence of observable disease at end of delayed
      primary debulking surgery), reason for delayed primary debulking surgery at initial
      diagnosis (nonresectable disease vs other reasons), and timing of intraperitoneal catheter
      insertion (intra-operative catheter insertion vs post-operative insertion).

        -  Phase II: Patients are randomized to 1 of 3 treatment groups.

             -  ARM 1: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured
                GFR or AUC6 if estimated GFR intravenous day 1; Paclitaxel 60 mg/m2 intravenous
                day 8. Cycles given Q 21 days x 3 cycles

             -  ARM 2: Paclitaxel 135 mg/m2 intravenous day 1 plus Cisplatin 75 mg/m2
                intraperitoneal day 1; Paclitaxel 60 mg/m2 intraperitoneal day 8. Cycles given Q
                21 days x 3 cycles (Phase II cisplatin arm closed to accrual on 2014-Feb-03)

             -  ARM 3: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured
                GFR or AUC6 if estimated GFR intraperitoneal day 1; Paclitaxel 60 mg/m2
                intraperitoneal day 8. Cycles given Q 21 days x 3 cycles.

      Patients also receive carboplatin IP on day 1. Treatment repeats every 21 days for 3 courses
      in the absence of disease progression or unacceptable toxicity.

        -  Expanded Phase II: Patients are randomized to 1 of 2 treatment groups.

             -  Arm I: Patients receive paclitaxel and carboplatin as in phase II, arm I.

             -  Arm III: Patients receive paclitaxel and cisplatin as in phase II, arm II or
                paclitaxel and carboplatin as in phase II, arm III.

      Patients complete quality of life questionnaires EORTC QLQ-C30, ovarian cancer module (EORTC
      QLQ-OV28), and FACT/GOG-Ntx at baseline, on day 1 of courses 2 and 3, at 3, 6 and 12 months
      after completion of study treatment, and then annually until disease progression, death, or
      initiation of second-line therapy.

      After completion of study treatment, patients are followed at 6 weeks, every 3 months for 2
      years, every 6 months for 2 years, and then annually until progression, death, or initiation
      of second-line therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>9-month progression rate post-randomization</measure>
    <time_frame>8 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Completion rate of treatment (based on toxic effects and feasibility)</measure>
    <time_frame>8 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxic effects as evaluated after each cycle and periodically after completion of therapy</measure>
    <time_frame>8 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>8 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life as measured by EORTC QLQ-C30, ovarian cancer module (EORTC QLQ-OV28), and FACT/GOG-Ntx questionnaires on day 1 cycle 2, day 1 cycle 3 and at end of last cycle</measure>
    <time_frame>8 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free and Overall survival</measure>
    <time_frame>8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxic effects</measure>
    <time_frame>8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlative biological studies</measure>
    <time_frame>8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic evaluation</measure>
    <time_frame>8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcomes associated with variation in nursing-related practices as measured by nursing management questions worksheet for IP chemotherapy administration on day 1 and 8 of each cycle of IP treatment (Phase II)</measure>
    <time_frame>8 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">275</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Peritoneal Cavity Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ARM 1: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured GFR or AUC6 if estimated GFR intravenous day 1; Paclitaxel 60 mg/m2 intravenous day 8. Cycles given Q 21 days x 3 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ARM 2: Paclitaxel 135 mg/m2 intravenous day 1 plus Cisplatin 75 mg/m2 intraperitoneal day 1; Paclitaxel 60 mg/m2 intraperitoneal day 8. Cycles given Q 21 days x 3 cycles (Phase II cisplatin arm closed to accrual on 2014-FEB-03)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ARM 3: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured GFR or AUC6 if estimated GFR intraperitoneal day 1; Paclitaxel 60 mg/m2 intraperitoneal day 8. Cycles given Q 21 days x 3 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Carboplatin AUC 5 if measured GFR or AUC6 if calculated GFR intravenous or intraperitoneal.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Cisplatin 75 mg/m2 intraperitoneal day 1</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Paclitaxel 135 mg/m2 intravenous day 1 plus Paclitaxel 60 mg/m2 intraperitoneal or intravenously day 8. Cycles given Q 21 days x 3 cycles</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>day 1 cycle 2, day 1 cycle 3 and at 3, 6, 12 mo then annually until disease progression, death or initiation of second-line therapy</description>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed ovarian epithelial, primary serous type peritoneal, or
             fallopian tube carcinoma

               -  Patients with ovarian cancer of the clear cell histology are eligible.
                  Histologic confirmation is preferably by biopsy or limited excision prior to
                  neo‐adjuvant treatment. If the diagnosis prior to neo-adjuvant chemotherapy is
                  based on cytology, histologic confirmation is required prior to randomization.
                  Histologic confirmation can be obtained at the time of debulking surgery by
                  intra-operative frozen section, thus permitting intra-operative randomization,
                  or by final pathologic review of the resected specimen if randomization is to be
                  performed following debulking surgery.

               -  Initial FIGO stage IIB-III disease

                    -  Stage IV disease allowed provided the only criterion for stage IV disease
                       is the presence of a pleural effusion confirmed to be associated with
                       positive cytology for ovarian cancer

          -  Completed ≥ 3 but no more than 4 courses of platinum-based neoadjuvant chemotherapy
             prior to the first debulking surgery

          -  Meets the following criteria for surgical treatment prior to randomization:

               -  Initial Diagnosis: No debulking surgery was attempted or completed.

               -  The patient's first cytoreductive (debulking) surgery must be after neoadjuvant
                  chemotherapy (Delayed Primary Debulking). The delayed primary debulking surgery
                  must be completed no more than 4 weeks after commencing administering of the
                  last cycle of neoadjuvant chemotherapy and must be completed no more than 6
                  weeks prior to randomization.

               -  Surgery will include total abdominal hysterectomy, bilateral
                  salpingo-oophorectomy, omentectomy and any additional procedures required to
                  achieve maximal cytoreduction with residual disease of 1 cm or less as assessed
                  by the surgeon at the end of surgery.

                    -  Delayed primary debulking surgery must be completed no more than 4 weeks
                       after the last course of neoadjuvant chemotherapy and must be completed no
                       more than 6 weeks prior to randomization

               -  Surgery will include total abdominal hysterectomy, bilateral
                  salpingo-oophorectomy, omentectomy, and any additional procedures required to
                  achieve maximal cytoreduction with residual disease of ≤ 1 cm as assessed by the
                  surgeon at the end of surgery

          -  No borderline ovarian tumors (i.e., tumors of low malignant potential) alone

          -  No mucinous tumor

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy ≥ 12 weeks

          -  Granulocyte count ≥ 1.5 x 10^9/L

          -  Platelet count ≥ 100 x 10^9/L

          -  Serum creatinine ≤ upper limit of normal (ULN) OR &gt; ULN to ≤ 1.25 ULN provided
             measured creatinine clearance is &gt; 60 mL/min

          -  Serum bilirubin normal

          -  AST/ALT ≤ 2.5 times ULN

          -  Fertile patients must use effective contraception

          -  Able (i.e., sufficiently fluent) and willing to complete the quality of life
             questionnaires

          -  Accessible for treatment and follow-up

          -  No history of other malignancy, except adequately treated nonmelanoma skin cancer,
             curatively treated carcinoma in situ of the cervix, or other solid tumors curatively
             treated with no evidence of disease for ≥ 5 years

          -  No uncontrolled atrial or ventricular arrhythmias including second or third degree
             heart block unless managed with implanted pacemaker

               -  Patients with a history of first degree heart block are eligible

          -  No documented myocardial infarction within the past 6 months preceding randomization
             (pretreatment ECG evidence only of infarct will not exclude patients)

          -  No diagnosis of bowel obstruction

          -  No serious illness or medical condition which would not permit the patient to be
             managed according to protocol including, but not limited to, any of the following:

               -  Prior allergic reactions to drugs containing cremophor or to compounds
                  chemically related to cisplatin, paclitaxel, or carboplatin

               -  Symptomatic congestive heart failure within the past 6 months or other
                  conditions which would lead to a contraindication of a high-volume saline
                  diuresis

               -  History of significant neurologic or psychiatric disorder which would impair the
                  ability to obtain consent

               -  Active uncontrolled infection

               -  Persistent peripheral neuropathy or hearing loss ≥ grade 2 resulting from prior
                  therapy

               -  Extensive intraperitoneal adhesion intra- or post-operatively which would impede
                  intraperitoneal treatment delivery

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior therapy for ovarian cancer, except for neoadjuvant platinum-based
             chemotherapy and surgery

          -  No concurrent intraperitoneal adhesion barriers

          -  No other concurrent anticancer treatment, including cytotoxic agents, biological
             response modifiers, immunotherapy, anticancer hormone therapy, or investigational
             drug therapy

          -  No other concurrent experimental drugs or anticancer therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen J. Mackay, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diane M. Provencher, MD, FRCS, FACOG</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Notre-Dame du CHUM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mercy-Springfield</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CoxHealth</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73190-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Utah (Huntsman Cancer Institute)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest CCOP - Multicare Health System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Cancer Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Fraser Valley Cancer Centre</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Health Authority B, Zone 2</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. H. Bliss Murphy Cancer Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Science Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University - Dept. Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUQ-Pavillon Hotel-Dieu de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Catalan de Oncologia - L'Hospitalet</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Fundacion Alcorcon</name>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico MD Anderson - Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Instituto Valenciano de Oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clatterbridge Center for Oncology - Liverpool</name>
      <address>
        <city>Wirral</city>
        <state>Bebington</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Hospital - Middlesex</name>
      <address>
        <city>Middlesex</city>
        <state>Northwood</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wexham Park Hospital</name>
      <address>
        <city>Berkshire</city>
        <state>Slough</state>
        <zip>SL2 4HL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George's Hospital - London</name>
      <address>
        <city>London</city>
        <state>Tooting</state>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie Hospital - Manchester</name>
      <address>
        <city>Manchester</city>
        <state>Withington</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Western General Hospital - Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James University Hospital - Leeds</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Women's Hospital - Liverpool</name>
      <address>
        <city>Liverpool</city>
        <zip>L8 755</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bartholomew's Hospital - London</name>
      <address>
        <city>London</city>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital - London</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hammersmith Hospital - London</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospital - London</name>
      <address>
        <city>London</city>
        <zip>W1T 4TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Marys Hospital - Manchester</name>
      <address>
        <city>Manchester</city>
        <zip>M13 0JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Churchill Hospital - Oxford</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Derriford Hospital - Plymouth</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>July 11, 2016</lastchanged_date>
  <firstreceived_date>October 9, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peritoneal cavity cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>stage II ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>malignant pleural effusion</keyword>
  <keyword>ovarian clear cell cystadenocarcinoma</keyword>
  <keyword>ovarian clear cell tumor with proliferating activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
